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Abstract
Kaposi’s Sarcoma (KS) originates from endothelial cells and it is one of the most overt angiogenic
tumors. In Sub-Saharan Africa, where HIV and the Kaposi Sarcoma-associated Herpes Virus
(KSHV) are endemic, KS is the most common cancer overall, but model systems for disease study
are insufficient. Here we report the development of a novel mouse model of KS where KSHV is
retained stably and tumors are elicited rapidly. Tumor growth was sensitive to specific allosteric
inhibitors (rapamycin, CCI-779, RAD001) of the pivotal cell growth regulator mTOR. Inhibition
of tumor growth was durable up to 130 days and reversible. mTOR blockade reduced VEGF
secretion and formation of tumor vasculature. Together, the results demonstrated that mTOR
inhibitors exert a direct anti-KS effect by inhibiting angiogenesis and paracrine effectors,
suggesting their application as a new treatment modality for KS and other cancers of endothelial
origin.
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INTRODUCTION
Kaposi’s Sarcoma (KS) is an aggressive cancer of the endothelial cell origin affecting
immune compromised patients, the elderly as well as children and adults in Sub-Saharan
Africa. KS is the most common cancer overall (men and women) in Namibia, Botswana,
Zimbabwe, Zambia, Malawi, Mozambique, Uganda, Ethiopia and parts of South Africa (1).
KS is an AIDS defining malignancy. It is regularly seen as a solid organ transplant
associated cancer in Southern Europe, the Mediterranean region, Turkey and Saudi Arabia
(2). Chang et al. identified Kaposi’s Sarcoma-associated Herpes Virus (KSHV) in any and
all forms of KS (3). For lack of known tumor-specific target pathways, KS is treated with
cytotoxic chemotherapy, now predominantly liposomal doxorubicin (Doxil™). Although,
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initial response rates are reasonable, subsequent failures are not uncommon (4). Drug
resistance has also been documented. Doxil™ is associated with toxicity and has a lifetime
dose limit. This motivated our experiments to establish a novel animal model for drug
evaluation and to explore the PI3K/Akt/mTOR pathway as a new target of intervention in
KS.
Morphologically, KS lesions appear as flat dermal ‘patches’ upon initial presentation. As the
lesion progresses, it goes from patch to plaque to nodule and the initial red color takes on a
darker, purplish hue. The characteristic color of these lesions is indicative of the high degree
of vasculogenesis and angiogenesis associated with KS. Angiogenesis in KS begins even
before the formation of a visible lesion. 100% of the KS tumor cells carry KSHV and
express the KSHV latency associated nuclear antigen (LANA) as the defining biomarker for
KS (5, 6). The tumor cells also express other viral proteins, which promote tumor cell
growth cell-autonomously or through induction of soluble factors, which act through
autocrine and paracrine mechanisms.
vGPCR is the KSHV homolog to human IL8 receptor; it can signal in the absence of ligand
binding, thus resulting in a constitutively active state (7–9). vGPCR can activate phospho-
inositide-3-Kinase (PI3K) as well as induce Vascular Endothelial Growth Factor (VEGF)
(10). Other viral signaling molecules, which can activate PI3K signaling, include K1 and
K15 (11, 12). As multiple (K1, K15, vGPCR) viral signaling molecules converge on the
PI3K pathway, we reasoned that KS is addicted to this pathway and that kinases within this
pathway represent promising drug targets.
PI3K is activated by membrane receptor signaling and phosphorylates its downstream target
Akt. Phosphorylated Akt in turn activates the mTOR kinases, which have multiple targets
that support cell growth (reviewed in (13, 14)). We, along with other groups, have shown
that the PI3K/Akt/mTOR pathway is constitutively activated in KS-infected cells as well as
in vGPCR and K1 driven cell culture models (12, 15–18).
Clinical observations also supported the importance of the PI3K/Akt/mTOR pathway in KS.
Stallone et al. (19) reported that switching the immune suppressive regimen of renal
transplant patients from CyclosporinA, which inhibits cyclophillin in T-cells, to rapamycin
(sirolimus), which inhibits mTOR (20), resulted in regression of KS lesions. Others have
reported similar cases (21–23); a few exceptions have also been noted (24, 25). Most
recently we completed a pilot study of AIDS-KS and found long-term disease stabilization
or partial responses in 6 of 7 (85%) HIV-positive patients (26). These clinical studies
allowed for two alternative hypotheses as to the mechanism of rapamycin and other
allosteric mTOR inhibitors (everolimus, temsirolimus), the so-called rapalogs (reviewed in
(27)). First, rapalogs changed either the type or the level of immune suppression and KS
tumor regression was secondary. This hypothesis is supported by the sometimes
spontaneous regression of KS after immune reconstitution of AIDS patients or after immune
suppression tampering of transplant recipients. Second, rapalogs have direct anti-tumor
effects as had been demonstrated for everolimus in renal cell cancer and temsirolimus in
mantle cell lymphoma (28–30). These anti-tumor effects could be impacting the tumor cell
directly or the supporting vasculature. Unique to KS both the tumor cell itself and the tumor-
feeding blood vessels are of endothelial origin.
To decide among these competing hypotheses we established a novel mouse model of KS,
which is dependent on the KSHV virus, and used it to evaluate a battery of structurally
different, FDA approved mTOR inhibitors: rapamycin/ Sirolimus, everolimus/ RAD-001
and Temsirolimus/ CCI-779. As controls we used Cyclosporine A and FK506 (Tacrolimus),
which is a macrolide that is structurally related to rapamycin, but does not inhibit mTOR
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(31). The latter control drugs modulate the immune status as efficiently as rapamycin, but
have no activity against mTOR. We found that all three rapalogs were equally effective in
multiple KS models. Rapalogs inhibited VEGF-1 secretion and arrested growth in immune
deficient mice by reducing intra-tumor ribosomal S6 phosphorylation, tumor growth and
neoangiogenesis. In this model rapamycin was superior to doxorubicin.
METHODS
Cell culture
All cell lines were cultured in DMEM supplemented with 100 μg/ml streptomycin sulphate,
100 U/ml penicillin G (Life Technologies, Carlsbad, CA, USA), and 10% FBS at 37°C in
5% CO2. Cell lines were obtained from the ATCC or derived in our laboratory. The cells
have been tested and authenticated. The method used was whole genome Affymetrix 6.0
SNP array. The cells were last tested by the aforementioned method at submission within
receipt or resuscitation from stock. The L1T2 cell line will be submitted to the ATCC.
Quantitative PCR for KSHV Genome
Genomic DNA was extracted using Wizard SV Genomic DNA Purification System, as per
manufacturer’s protocol (Promega, Madison, WI) and quantitative PCR (qPCR) was used to
detect the viral genome in the different KS cell lines as per our previous publications (32).
CGH Analysis
Genomic DNA was extracted as above and hybridized to the 6.0 GeneChip Human Mapping
Array that uses >906 600known SNP and 946 000 CNV markers (Affymetrix). Data
analysis was performed using Partek Genomics Suite as described previously (33), and
normalized to tert-immortalized human vein endothelial cell (HUVEC).
Immunofluorescence
Cells were cultured overnight on glass coverslips in 6-well plates (Falcon-BD Biosci. Inc,
San Jose, CA). They were then washed in PBS followed by protocol for immune
fluorescence as described(34). Primary mouse anti-LANA (1:600 dil.) (Novocastra Lab Ltd.,
Newcastle, UK), rabbit anti-S6 ribosomal protein, Alexa Fluo® 488 conjugated anti-
phospho-S6 ribosomal protein for both S235/236 and S240/244 residues (1:200 dil.) (Cell
Signaling Tech., Inc., MA) were used for immunofluorescence. Images were taken on
LEICA DM4000B fluorescence microscope (Leica, Heidelberg, Germany) equipped with a
63/1.4–0.6 numerical aperture (NA) objective and a Q-Imaging Retiga 2000RV camera.
Raw microscopy image stacks were deconvoluted using Simple PCI™ (Hamamatsu Corp.,
Sewickley, PA, USA) 2D Blind Deconvolution that iteratively applies AutoQuant Imaging
(Media Cybernetics, Inc. Bethesda, MD) proprietary algorithm to remove blur and generate
high clarity images, and stored as tiff files. Images were assembled in Photoshop CS4 under
MacOsX 10.7.
Tumor formation
Cells were counted, washed once in ice-cold phosphate-buffered saline (PBS, Cellgro
Mediatech, Inc., Herndon, VA) and indicated cell doses were diluted into 100 μl PBS and
mixed with 100 μl growth factor-depleted Matrigel (BD Biosciences, Bedford, MA). 1x106
cells were injected sub-cutaneously into the flank of C.B.17-PkrdcSCID mice (Jackson
Laboratory, Bar Harbor, MN) following our previously validated procedures (35). The mice
were observed every day for the presence of palpable tumors. Drug or vehicle was injected
intra-peritoneally at the indicated dosing schedule. Tumor diameters were determined by
caliper measurements. Tumor volume calculated as V = a * b * c, where a, b and c are the
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three diameters (length, breadth and width) of the tumor. The tumors were excised from the
site of injection and fixed in formalin (Fisher Diagnostics, Middletown, VA) for subsequent
analysis.
Blood Rapamycin Quantification
Blood was collected from the animals by cardiac puncture 48hrs after the last intra-
peritoneal injection of Rapamycin at either 2.5 mg/kg or 5 mg/kg dose. Care was taken to
ensure that blood was directly collected into EDTA-coated tubes (BD, Franklin Lakes, NJ)
to prevent any coagulation. Rapamycin levels were determined from whole blood by HPLC-
MS-MS using Nova_Pak® columns (Waters Corp, Milford, MA) offering sensitivity in the
2–50 ng/ml range.
Immunohistochemistry
Tumors were removed and processed as per (17) and stained using the appropriate primary
antibodies: phospho-S6 ribosomal protein (Ser 235/236) monoclonal antibody (1:100 dil.)
and phospho-4EBP1 (Ser 65) antibody (1:50 dil.) from Cell Signaling Inc. (Boston, MA).
Sections were imaged using a LEICA DM LA histology microscope (Leica, Heidelberg,
Germany) equipped with a 10x/0.25 numerical aperture (NA), a 40x/0.75 NA N plan
objective, or HC PLAN APO 20x/0.70 NA and Leica DPC 480 camera. Images were stored
as TIFF files under Mac OS X10.5. Staining intensity was assessed using the FRIDA
(Framework for Image Dataset Analysis) as outlined (36). Briefly, FRIDA measures the
pixel intensity of the tumor section based on a user defined ‘positive’ stain and we plotted
the square root of this total area intensity. To determine the degree of significance, we used
ANOVA implemented in the R statistics environment (version 2.14.1).
Tumor Vasculature Staining
Tumor vasculature was determined using commercially available Periodic Acid Schiff
(PAS) staining system following manufacturer’s recommendations (Sigma Aldrich, St.
Louis, MO). Sections were imaged, PAS staining quantified using FRIDA and significance
determined, as above.
VEGF Quantification
VEGF levels in the culture supernatants were determined using commercially available
VEGF ELISA assay as per manufacturer’s recommendations (PeproTech, Rocky Hill, NJ).
The biological activity of secreted VEGF (supplemental figure 1) was ascertained by
sprouting assay as described (37).
RESULTS
A robust, human, KSHV-positive mouse model for KS
Despite the identification of KS nearly two decades ago, there is a dearth of pre-clinical
models for KS. Explants from KS biopsies have been successful to a limited degree (two
cell lines in 20 years (38, 39)) but rapidly lose the viral episome. Thus they no longer
represent the full spectrum of molecular interactions present in the primary tumor. The best-
characterized example until recently was the SLK cell line. It was isolated from an oral KS
biopsy of an HIV-negative male (38) and at the time of tissue procurement expressed KSHV
LANA and exhibited the KS defining spindle cell morphology. KSHV was lost, but the
spindle cell morphology was retained and SLK cells form tumors in immune deficient mice.
This year it was shown that the SLK cell line used in laboratories throughout the world has
in fact become contaminated with the kidney carcinoma cell line Caki-1; a second KS-
Roy et al. Page 4













derived cell line KS-Y1 was also shown to be contaminated by an irrelevant cell line (40).
This leaves the field bereft of human tumor models for this cancer.
De novo infection of human endothelial cells in culture by KSHV is possible, but here too
the virus is rapidly lost unless maintained under drug selection (37, 41–43). The exceptions
are two cell lines (TIVE-E1 and TIVE-L1) that were derived by infection of telomerase-
immortalized, umbilical cord-derived endothelial cells (44). These cells maintain KSHV in
the absence of drug selection, secrete IL6, IL8, VEGF and form tumors in nude mice, albeit
slowly.
The L1T2 cell line was established from a sub-cutaneous tumor that developed upon
injecting TIVE-L1 cells into C.B.17-PkrdcSCID mice (figure 1, panel A). L1T2 retained the
tumor forming potential of the parental cell line. They induced uniform, fast growing, sub-
cutaneous (s.c.) tumors in C.B.17-PkrdcSCID (figure 1, panel B) and nu/nu mice (data not
shown). At the 106 cells dose 100% of the animals developed palpable tumors after only 2
days, which grew exponentially for up to 21 days (Table 1). This phenotype held true at the
105-cells dose as well (data not shown). The cells express the viral latent protein LANA in
the typical punctate pattern (Figure 1, panel C). The punctate pattern requires the presence
of KSHV terminal repeats which bind LANA (45), and the so-called “LANA-dots” correlate
directly with the number of viral episomes (46). The L1T2 induced tumors were highly
proliferative as demonstrated by Ki-67 staining (Figure 2, panel A–B), and in the tumor
retained expression of the endothelial marker genes CD31 (Figure 2, panel E–F) and VEGF-
R3 (Figure 2, panel C–D) as well as LANA (Figure 2, panel G–H). The cells retained the
complete viral episome as demonstrated by real-time qPCR with primers in each orf across
the genome (Figure 2, panel J). L1T2, for the first time, provides an animal model for KS
based on human cells, that maintains the virus in the absence of selection, that is fast,
economic, robust and reproducible enough for large scale in vivo drug evaluation.
Rapamycin is efficacious against KS xenograft tumors in vivo
To test the hypothesis that rapalogs have direct anti-tumor activity against KS and that this
activity is independent of any immune modulating properties that these agents may also
have, we treated established xenografts in C.B.17-PkrdcSCID mice that lack any immune
effector cells with rapamycin and its various analogs. First, we tested TIVE-E1 and TIVE-
L1 cells, which had previously been established as model systems to study KS pathogenesis
in nu/nu mice (44). TIVE E1 and L1 represent two independent clones of telomerase-
immortalized, KSHV infected endothelial cells, each of which sustained independent
chromosome rearrangements (Figure 2, panel J). TIVE-L1 (figure 3, panel A) and TIVE-E1
(figure 3, panel B) cells were injected s.c. and upon formation of palpable tumors, animals
received rapamycin at 3 mg/kg/day 3 times a week, or vehicle. Figure 3 panels A and B
compare tumor growth in rapamycin and mock treated animals. In each cohort drug treated
animals showed significantly smaller tumors than mock treatment (p<0.05 by repeated
measurements, random effects model). Next, we tested KSHV-negative SLK cells, which
thus far were the standard for pre-clinical drug testing in KS (figure 3, panel C). Upon
formation of palpable tumors, animals received rapamycin at 2.5 mg/kg/day 3 times a week,
5 mg/kg/day 3 times a week, or vehicle. At 5 mg/kg Rapamycin was very effective against
tumor progression; however, it adversely affected overall health of the animals (table 1). At
2.5mg/kg of Rapamycin was equally as effective in tumor inhibition as 5 mg/kg/day dose
together with improvement in survival and overall health (p<0.05 by repeated measurements
random effects model). Finally, we tested KSHV-positive L1T2 cells (figure 3, panel D).
Upon formation of palpable tumors, animals received rapamycin at 2.5mg/kg/day 3 times a
week, or vehicle. Again, rapamycin effectively inhibited tumor growth compared to vehicle
control (p<0.05 by repeated measurements random effects model).
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To establish equivalency amongst the different rapalogs we also tested temsirolimus and
everolimus in the L1T2 system. Each resulted in significant tumor inhibition. We also tested
the ATP-competitive mTOR inhibitor PP242 (table 1). This resulted in tumor reduction, but
was not superior to allosteric rapalogs. FK506, which is structurally similar to rapamycin,
and which like rapamycin binds FKBP (but not mTOR), had no activity (table 1). Table 1 is
a summary of all the studies we conducted. These show that rapalogs are efficacious against
tumors, irrespective of whether they were isolated from KS biopsies (SLK) or generated
following de novo infection of endothelial cells (E1, L1, L1T2). Single agent rapalogs,
irrespective of their particular structure, resulted in prolonged (up to 130 days) growth
inhibition. Of note, each experiment was conducted in parallel with a similar size group of
mock treated animals, which received the same cell aliquot. The group size n in table 1
refers only to the size of the experimental group. In total we observed significant raplog-
dependent tumor inhibition in 85 animals.
Rapalog dosing presents a significant challenge in the clinic, especially considering that
rapalogs are metabolized by the cytochrome P450 family members in the liver (47). Even in
culture, the IC50 for rapamycin may vary more than 1000-fold between cancer cell lines
(48). The reason is unknown and may have as much to do with drug transport as with
pathway resistance mutations. P450 is expressed by the tumor endothelial cells within KS
lesions (Roy and Dittmer, unpublished). Therefore, we optimized the dosing regimen
required to obtain therapeutic drug trough levels, while minimizing toxicity. Note that our
dosing is rather infrequent compared to other experimental designs (16, 49), which require
daily dosing. At 5mg/kg doses of rapamycin the animals exhibited weight loss, lethargy and
had to be sacrificed despite robust inhibition of tumor progression. At 1.5mg/kg, the animals
remained healthy throughout extended treatment, but anti-tumor activity was lost (data not
shown). Based on these data we established the optimal dose for long-term rapamycin
treatment in C.B.17.PKRDscid mice at 2.5 mg/kg 3 times a week. Next, we assessed the
actual levels of Rapamycin in the blood stream of the animals. Figure 2, panel F shows that
at 2.5mg/kg doses we are able to maintain a steady level of drug in the blood compared to
5mg/kg (figure 2, panel E) where blood levels spike early on and presumably cause drug
toxicity. In summary, we established the efficacy of multiple, chemically distinct rapalogs
(sirolimus/rapamycin, temsirolimus, everolimus), and the ATP-competitive mTOR inhibitor
PP242 in four distinct xenograft models of KS. We established 2.5 mg/kg 3 times a week as
a low intensity regimen, which resulted in long-term (> 60 days) growth suppression and
showed that this dosing regimen leads to sustained, systemic trough levels of 20 ng/ml,
which was the target trough levels in recent clinical trials of this drug family (26).
Rapamycin inhibits phosphorylation of mTOR targets S6-ribosomal protein and 4E-
Binding Protein in vivo
Having extensively validated our tumor model, we used it to elucidate the mechanism of
action of allosteric rapalogs in KS. Phosphorylation of ribosomal S6 (S6R) protein is
considered a robust readout for mTOR activation. We treated L1T2 cells with rapamycin (5
μM corresponding to 4.5μg/ml) in culture and measured S6 phosphorylation. Figure 4
shows immunofluorescence staining for total (panels A and D) and phosphorylated S6R
(pS6R) (panels B, E for pS6R (Ser235/236) and panels C, F for pS6R (Ser240/244)). As
expected S6 is expressed at high levels in L1T2 cells and heavily phosphorylated at both
composite sites (figure 4, panels A, B and C). Upon treatment with rapamycin, total S6
expression remained unchanged, while S6 phosphorylation was completely abolished
(without loss of cell viability). This demonstrates that rapalogs inhibit their molecular targets
in our KS-tumor model.
Because we were treating established tumors in the mouse model where rapalogs lead to
sustained growth inhibition, and only later leads to necrosis due to lack of nutrient and
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oxygen (see below), we were able to measure molecular markers of mTOR inhibition in
early tumors in vivo. The L1T2 tumor morphology of mock treated tumors was analogous to
KS biopsies as judged by Hematoxilin stain. The drug treated tumors were similar, except
that the interior of the tumor mainly consisted of necrotic tissue, compared to mock (data not
shown). Treatment with rapamycin resulted in dramatically reduced levels of pS6R
(Ser235/236) compared to both mock and FK506 treatment (figure 4, panels G–I). In
addition to pS6R, a second target of mTOR is 4EBP1 (14, 50). Immunohistochemical
staining of tumor sections revealed down-regulation of 4EBP1 phosphorylated at Ser65
following rapamycin treatment, but no change in mock and FK506 treated tumors (figure 4,
panels J–L). Rapamycin reduced S6 and 4E-BP1 phosphorylation in vivo (figure 4, panel M,
with p≤0.05 by two-way ANOVA). This demonstrates that the molecular mechanism of
action of rapalogs in KS is the same as in other cancers, such as KSHV-associated primary
effusion lymphoma (PEL) (17). It validates the use of pS6 and p4E-BP1 as novel biomarkers
for rapalog therapy in KS.
Rapamycin inhibits VEGF secretion and associated vasculature development
KS tumors are characterized by their atypical purple color indicative of vastly increased
vasculature and angiogenesis. Furthermore, KS tumors are rich in VEGF, IL-1beta, PDGF
and other endothelial cell growth factors (51–53). This phenotype is recapitulated in our
murine model. Rapalogs are known to inhibit endothelial-cell mediated tumor neo-
angiogenesis in addition to direct tumor growth (54, 55). We therefore hypothesized that
some of the KS-specific targets of rapamycin are paracrine growth factors involved in tumor
vasculature development. Because of the endothelial cell lineage of KS tumors, these same
growth factors can also function in an autocrine manner, which may explain the increased
sensitivity of KS to rapalogs.
VEGF is a key angiogenesis-promoting factor secreted by KS and other tumor cells. TIVE-
E1, -L1, SLK and L1T2 cells all secrete VEGF, as detected in the culture supernatant. We
measured between 2,000 – 4,000 pg/ml in the supernatant KS-like cells over a 48-hour
period. By comparison, KSHV-infected lymphoma cell lines secreted 200 – 400 pg/ml in the
same, luminex-based, assay. The cells secreted similarly high levels of IL-6 and IL-8 (Roy
and Dittmer, unpublished). Rapamycin down regulated levels of VEGF secreted by TIVE-
L1 cells in culture (figure 5, panel A). We conducted a time course followed by drug
washout experiment to assess both the production and accumulation of VEGF in culture
supernatant. We detected levels of secreted VEGF (isoform A) in cells treated with 0.5μM
(0.45μg/ml) and 5μM (4.5ug/ml) rapamycin over 96-hours (figure 5, panel A). Upon drug
withdrawal, the cells recovered slowly and gradually increased VEGF secretion. Similar
results were noted for TIVE-L1, SLK and L1T2 cells (data not shown). For KSHV infected
BCBL-1 cells, we found that conditioned media from rapamycin treated cells no longer
supported HUVEC tubule formation (supplemental figure 1). This demonstrates that
rapamycin inhibits biologically active VEGF, which is an autocrine growth factor in KS
(56).
The xenograft model constitutes a much more demanding setting than in vitro culture and
requires cancer cells to establish and maintain an optimal microenvironment for survival.
We hypothesized that reduction of growth factors by rapalogs would have a pronounced
impact on tumor progression. To address this, we utilized PAS staining, which marks the
vasculature directly, rather than relying on just one particular biomarker protein, thereby
detecting the overall physiological impact (57, 58). Rapamycin resulted in a sustained tumor
vasculature defect (figure 5, panels B). Rapamycin-treated tumors had less ordered, less
mature vessel formation compared to mock and FK506 treatment. The tumor cells appeared
in isolated, clumped nests rather than each cell being enmeshed in supportive stroma and
vasculature with the KS associated slit-like morphology. Quantification of PAS-positivity
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demonstrated a statistically significant reduction in staining (figure 5, panel C). Rapamycin-
treated tumors had significantly reduced branching indicative of immature vasculature and
poor angiogenesis. Since clinically KS is among the most highly angiogenic sarcomas,
second only to hemangioma, we conclude that reduction of growth of tumor supporting
endothelial cells by rapalogs and inhibition of paracrine factors (like VEGF) contributes to
the efficacy of the rapalogs against this particular cancer.
Rapamycin and Doxorubicin combination therapy
Having demonstrated single-agent efficacy of multiple rapalogs against KS, we explored the
efficacy of rapamycin in the adjuvant setting. Specifically, we wanted to test the hypothesis
that adding doxorubicin to rapamycin would result in increased cytotoxicity. We confirmed
this hypothesis in the cell culture model of PEL (supplemental Figure 2); however the in
vivo studies yielded a surprising result. Pre-formed L1T2 tumors were treated with four
different regimens: (1) 2.5mg/kg Rapamycin (intra-peritoneally (i.p.) 3x weekly), (2) 4 mg/
kg Doxorubicin (i.p. 5x weekly), (3) 2.5mg/kg Rapamycin (i.p. 3x weekly) + 4 mg/kg
Doxorubicin (i.p. 5x weekly) or (4) mock. Individually, both drugs inhibited tumor
progression (table 1). Nonetheless, the combination treatment did not show synergy or an
additive effect on tumor growth. We utilized PAS staining to investigate tumor angiogenesis
(figure 6). As expected untreated L1T2 tumors were highly vascularized and individual cells
were neatly packed in a supportive, mesh-like vascular microenvironment (figure 6, panel B
and C). Rapamycin treatment (panels D, E) destroyed the tumor vasculature (p≤0.005 by
Wilcox Sum Rank test), which we quantified by counting the number of PAS positive
branches in several tumor sections. Branch points, defined as two or more finger-like PAS
vessels at a common point, were averaged from five distinct regions for each tumor section.
Doxorubicin did not affect the tumor vasculature (figure 6, panel A). The combination
treatment shows a novel phenotype: tumor cells were nested together in relatively few
islands separated by extended thicker slit-like structures (figure 6, see panel H and I and
double arrows). This may explain the absence of synergy between rapamycin and
doxorubicin in this model. By restricting angiogenesis rapamycin restricts at the same time
the flow of nutrients and oxygen to the tumor (resulting in growth inhibition) and the flow of
the doxorubicin drug, thus limiting the efficacy of the cytotoxic drug. This result has
important clinical ramifications. It argues against simultaneous therapy of rapalogs and
cytotoxic drugs, which in the extreme may foster the emergence of drug resistant tumor cells
due to sub-optimal exposure to the cytotoxic drug.
DISCUSSION
A large body of clinical evidence suggests that in the solid organ transplant setting switching
to a rapamycin containing immune suppressive regimen leads to KS regression or lowers the
risk of KS development (21–23, 59, 60). Similar data are missing for AIDS KS, endemic KS
or classic KS or for the use of rapalogs as dedicated, single agent anti-tumor drugs against
KS. No data exist for the newer rapamycin analogs everolimus, temsirolimus, or the ATP-
competitive inhibitors of mTOR (27). Here, we tested the hypothesis that mTOR inhibitors
have anti-tumor activity against KS, and we describe a new mechanism that could explain
the extraordinary sensitivity of KS to rapamycin. This work was predicated on development
of a new human tumor model of KS, which is robust, fast and mimics all the phenotypes
associated with the human tumor (figure 1). It was driven by the insights that (i) KS is an
endothelial cell lineage tumor (42, 61, 62), (ii) KS is dependent on autocrine and paracrine
growth factors, (iii) extensive neoangiogenesis and, (iv) rapalogs stymy tumor growth in
common cancers by inhibiting the host endothelial cells comprising the tumor vasculature
and microenvironment as well as through direct inhibition of tumor cell activity (14).
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For the purpose of this discussion we define rapalogs functionally as inhibitors of mTOR, as
opposed to FK506, which has a similar chemical structure as rapamycin, but does bind to or
inhibit mTOR. All rapalogs tested induced tumor regression of preformed KS-like human
tumors in our xenograft model (figure 2, table 1). Rapalog efficacy did not depend on
immune system modulation, since the host animals were deficient for B, T and NK cells and
since we achieved long-term, sustained responses with a 3x per week dosing regimen.
Rapalog efficacy did not depend on the presence of KSHV, since KSHV-negative SLK cell
tumors were also inhibited. This is expected since SLK cells exhibit the same signs of PI3K/
Akt/mTOR activation, i.e. phosphorylation of key residues, as KS tumors (36), and as
KSHV-induced KS cell lines. Rapalogs decreased phosphorylation of S6 ribosomal protein
and 4EBP-1 in vivo (figure 4), demonstrating that they inhibit the intended molecular targets
downstream of mTOR. The anti-tumor effect was reversible in vivo: upon withdrawal of the
rapalogs the tumors grew back uniformly (supplemental figure 3). In contrast, two
chemically related drugs Cyclosporine-A (data not shown) and FK506 had no anti-tumor
effect. This is particularly interesting since FK506 like rapamycin also binds to FKBP12, but
cannot bind mTOR (63). It supports the specificity of action of the rapalogs. The ATP-
competitive inhibitor PP242 also inhibited tumor progression in vivo, but was not superior
to the allosteric mTOR inhibitors. This validates mTOR as a bona-fide drug target in KS and
provides a solid biological rationale for future clinical trials.
We uncovered a novel mechanism of action for mTOR inhibitors that is specific to KS. The
rapalogs inhibited VEGF secretion by the KS tumor cells (figure 3) as well as VEGF
secretion in KSHV-dependent lymphomas (supplemental figure 2). We surmise that the
translational arrest induced by mTOR inhibition is not universal, but preferentially affects
autocrine growth factors of endothelial lineage cells and KS tumor cells. This is analogous
to the situation in PEL, where we showed previously that rapamycin stopped lymphoma
growth by inhibiting the essential autocrine growth factors IL6 and IL10 (17). This may
explain the differential response of different human cancers to rapalogs. Cancers, like KS,
that still depend heavily on pro-angiogenic and growth factors to sustain elevated PI3K
signaling are susceptible to mTOR inhibitors. Cancers that evolved growth factor
independence such as hormone resistant prostate cancer or estrogen receptor negative breast
cancer may be less responsive to mTOR inhibitors.
Finally, we explored the combination therapy of rapamycin with the prototypic cytostatic
drug, doxorubicin, which represents the current standard of care for KS. We did not find any
benefit of combining these two drugs in vivo. This represents a cautionary note in regards to
combining mTOR inhibitors with other drugs, as mTOR inhibitors may inhibit
neovascularization and sprouting of non-transformed endothelial cells (figure 6), thereby
potentially limiting drug delivery to the tumor.
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Figure 1. Establishment of L1T2 as a robust KS-like cell line in culture and in vivo
Panel A represents the schematic used to isolate L1T2 cells from explanted TIVE-L1
tumors. Cells were explanted from subcutaneous tumors formed in C.B.17-PkrdcSCID mice
injected with TIVE-L1 cells. Both TIVE-L1 and subsequent L1T2 cells secreted pro-
angiogenic factors VEGF and IL-8 in culture. Panel B shows a box and wisker plot of tumor
onset and progression in C.B.17-PkrdcSCID mice. The X-axis represents days post-injection
and the tumor volume (n = 8) in mm3 on the Y-axis. The red dot denotes the median, the
box denotes 25th and 75th percentile, and the whiskers denote the range of the data. Panel C
shows immunofluorescence staining for the presence of LANA (green) to indicate the
presence of the viral episome in culture. The upper panel is in the presence of anti-LANA
primary antibody whereas the lower panel shows secondary only control. The nucleus is
counter-stained with DAPI (blue).
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Figure 2. Characterization of the L1T2 cell line
Panel A–H show immunohistochemistry analysis of L1T2 xenografts using antibodies
associated with cell proliferation: Ki-67 in panel A, VEGFR-3 in panel C, CD31 in panel E
and LANA in panel G. Panels B, D, F and H show the respective no primary antibody
control sections on the same slide. Brown indicates the positivity of staining. Nuclei were
counterstained with hematoxilin (blue). All images are shown at 200x magnification. Panel I
shows the genomic copy number variation across chromosome 1 for the TIVE-E1 (red dots)
and TIVE-L1 (blue dots) cell line relative to KSHV-infected, tert-immortalized HUVEC
cells analyzed in parallel. Known transcript clusters are indicated on top and chromosome
coordinates on bottom, with the heatmap and dot-plot representations of copy number
variations in between. The vertical axis refers to the DNA content relative to control. Panel
H shows a heatmap representation of real-time qPCR array analysis of total DNA from three
independent aliquots (a,b,c) of L1T2 cells using 175 primer pairs distributed across the
entire KSHV genome. Aliquots of BC1 cells are used as positive control and water as non-
template control (ntc). Red indicates presence and blue represents absence of a discernable
PCR product.
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Figure 3. Effect and dosing scheme for rapamycin on different KS-like cell lines
Panels A shows the effect of rapamycin (3mg/kg/day dose) (n = 6) compared to vehicle
treatment (n = 6) in TIVE-L1 and panel B in TIVE-E1 xenografts. Panels C shows the effect
of rapamycin (2.5mg/kg/day dose) on SLK xenograft tumors (n = 8) compared to vehicle
treatment (n = 6). Panel D compares the effectof rapamycin (n = 9) to FK506 (n = 9)
treatment against L1T2 xenografts. In each of the panels A–D, the X-axis represents days
post-injection and Y-axis shows tumor volume in cm3. The dot denotes the median, the box
denotes 25th and 75th percentile, the whiskers the range of the data. Panel E is the
quantification of blood levels of rapamycin 48hrs following the last dose either at 5mg/kg
and panel F at 2.5mg/kg dosing concentration. The X-axis represents the total number of
doses, either at 2.5mg/kg/day or 5mg/kg/day whereas the actual level of rapamycin in the
blood is shown on the Y-axis in ng/ml.
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Figure 4. Downregulation of phosphorylated ribosomal S6 protein and eIF4E binding protein
(4EBP1) following rapamycin treatment
Panels A–F represent immunofluorescence staining of L1T2 cells. Panels A, B and C
represent mock treatment, panels D, E and F are treated with 5uM rapamycin (4.5 μg/ml).
Panels A and D represent staining for total S6R protein whereas panels B, E and C, F show
S6R phosphorylation on residues S235-236 and S240-244, respectively. This staining is
shown in green, the nucleus is in blue (counterstained with DAPI) and KSHV LANA
staining in red. Panels G–L show immunohistochemical staining for mTOR downstream
effectors pS6R (G, H, I) and p4EBP1 (J, K, L) in tumor sections treated with mock (G, J),
2.5mg/kg rapamycin (H, K) or 2.5mg/kg FK506 (I, L). The nuclei are denoted in blue
(Hematoxylin counter-stain). Panel M is the quantification of staining for panels G–L, where
the X-axis represents the square root of total area positive for pS6R (S235-236) and p4EBP1
(S65) while the Y-axis are the different treatment groups. The dot denotes the median, the
box denotes 25th and 75th percentile, the whiskers the range of the data.
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Figure 5. Treatment with rapamycin inhibits angiogenesis
Panel A shows the effect of treatment of TIVE-L1 cells in culture with rapamycin (0.5μM or
5μM) compared to vehicle on secreted levels of VEGF. The X-axis denotes time points in
days (up to 96 hours post-treatment) whereas the Y-axis represents mean levels of VEGF in
ng/ml. The dot denotes the median, the box denotes 25th and 75th percentile, and the
whiskers show the range of the data. Panel B shows representative sections demonstrating
the tumor vasculature using PAS staining for vehicle, 2.5mg/kg rapamycin and 2.5mg/kg
FK506 treated tumors. PAS marks the mature vasculature in pink to show that treatment
with Rapamycin resulted in a near complete disintegration of vascular network within the
tumor compared to mock or FK506 treatment. Panel C is the quantification of PAS staining
where the X-axis denotes the different treatment groups and the Y-axis represents square
root of area of the section that was PAS positive. The line denotes the median, the box
denotes 25th and 75th percentile, the whiskers the range of the data. Significance (p-value) is
calculated using ANOVA.
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Figure 6. Combination treatment using Rapamycin and Doxorubicin
Panel A shows the number of vascular branches after treatment with vehicle, doxorubicin or
rapamycin. The line denotes the median, the box denotes 25th and 75th percentile, and the
whiskers the range of the data. Significance (p-value) is calculated using ANOVA. Panel B–
I show PAS staining of the tumor for the different treatment groups at 100X and 400X
magnifications. Blue/gray indicated cell nuclei and red/purple the surrounding
microvasculature. The double arrows provide for a visual aid to gauge the size of the vessel
free tumor cell nests.
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